The Rapid Deployment Vaccine Collaborative is a 501(c)(3) nonprofit formed to enable rapid production and deployment of safe and effective pathogen countermeasures — vaccines, antivirals, and beyond — in the earliest days of an outbreak, when speed matters most and institutional response is slowest.
We create proof-of-principle demonstrations of early-stage vaccines and antivirals, and we freely share methods and protocols for decentralized production and self-administration. Our two foundations are self-production and self-administration: the building blocks of distributed, democratic biosecurity infrastructure.
Beginning in March 2020, in less than one month, we designed, produced, and self-administered the first of several progressive generations of nasal vaccines against SARS-CoV-2. We published every methods and protocol document online in a series of white papers under CC BY 4.0 and the Open COVID Pledge.
Nasal SARS-CoV-2 peptide vaccine
Our protocol for a peptide-conjugate intranasal vaccine, optimized across five revisions for breadth and durability against emerging SARS-CoV-2 variants.
Modernized variolation
Protocols for collecting mucus samples, inactivating viruses, and administering variolation safely. Additional protocols for decentralized sample collection and sharing.
Vaccine factories in a tube
Protocols for using genetically-modified yeast to generate vaccine factories in a tube. Vaccines can be delivered orally, nasally, or both.
AI for rapid drug repurposing and antiviral combinations design
Leveraging advances in open source data and AI to repurpose existing drugs and GRAS compounds as antivirals. New techniques for combining several weak antivirals into powerful combinations.
Radvac is building the open infrastructure required to respond to biological threats in hours or days, not months or years.